Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.
Original Source
Read the full article at Cnbc →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.